Cargando…
Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patients
BACKGROUND: Monogenetic inborn errors of metabolism cause a wide phenotypic heterogeneity that may even differ between family members carrying the same genetic variant. Computational modelling of metabolic networks may identify putative sources of this inter-patient heterogeneity. Here, we mainly fo...
Autores principales: | Odendaal, Christoff, Jager, Emmalie A., Martines, Anne-Claire M. F., Vieira-Lara, Marcel A., Huijkman, Nicolette C. A., Kiyuna, Ligia A., Gerding, Albert, Wolters, Justina C., Heiner-Fokkema, Rebecca, van Eunen, Karen, Derks, Terry G. J., Bakker, Barbara M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478272/ https://www.ncbi.nlm.nih.gov/pubmed/37667308 http://dx.doi.org/10.1186/s12915-023-01652-9 |
Ejemplares similares
-
Plasma carnitine concentrations in Medium‐chain acyl‐CoA dehydrogenase deficiency: lessons from an observational cohort study
por: Jager, Emmalie A., et al.
Publicado: (2022) -
Transcriptome analysis suggests a compensatory role of the cofactors coenzyme A and NAD(+) in medium-chain acyl-CoA dehydrogenase knockout mice
por: Martines, Anne-Claire M. F., et al.
Publicado: (2019) -
The promiscuous enzyme medium-chain 3-keto-acyl-CoA thiolase triggers a vicious cycle in fatty-acid beta-oxidation
por: Martines, Anne-Claire M. F., et al.
Publicado: (2017) -
In vitro and in vivo consequences of variant medium-chain acyl-CoA dehydrogenase genotypes
por: Touw, Catharina ML, et al.
Publicado: (2013) -
Enantiomer‐specific pharmacokinetics of D,L‐3‐hydroxybutyrate: Implications for the treatment of multiple acyl‐CoA dehydrogenase deficiency
por: van Rijt, Willemijn J., et al.
Publicado: (2021)